FDA Grants Full Approval to Tecartus CAR-T Therapy for Mantle Cell Lymphoma

Gilead Sciences announced Wednesday that the U.S. Food and Drug Administration granted full traditional approval to Kite's Tecartus (brexucabtagene autoleucel), a CAR-T cell therapy for adults with relapsed or refractory mantle cell lymphoma. The decision completes a post-marketing requirement the FDA had set when it first cleared the therapy under its Accelerated Approval pathway, converting that conditional status into a full regulatory endorsement grounded in confirmed clinical evidence.

The approval rests on the totality of evidence from the ZUMA-2 clinical trial, identified on ClinicalTrials.gov as NCT02601313. Confirmatory efficacy, safety, and pharmacokinetic data came from Cohort 3, which enrolled patients who had relapsed or were refractory after one or more prior lines of therapy and had not previously received a Bruton tyrosine kinase inhibitor, making them BTKi-naïve at the time of treatment. Results showed high response rates and durable outcomes consistent with earlier evaluations across the trial.

Michael Wang, M.D., lead investigator for ZUMA-2 and a professor at MD Anderson Cancer Center, said the confirmatory data "reinforces our confidence in the overall profile of brexu-cel" and that it provides "important information to help guide treatment decisions in the relapsed or refractory setting for appropriate patients."

Mantle cell lymphoma is a rare form of non-Hodgkin lymphoma that predominantly affects older men and frequently progresses quickly after relapse. Gilead emphasized that patients who relapse face an aggressive disease course with historically limited options, positioning Tecartus's deep and durable responses as clinically significant in that context.

Full approval carries practical consequences well beyond scientific validation. Accelerated approvals carry residual regulatory uncertainty that can complicate payer coverage determinations; confirmation of efficacy typically broadens that acceptance. For Gilead and Kite, the upgrade can influence hospital investment in cell-therapy infrastructure and referrals to the specialized centers capable of delivering CAR-T treatment.

Those centers face ongoing implementation pressures. Tecartus is an autologous therapy, meaning each course of treatment is manufactured from the individual patient's own T-cells, a process that demands substantial manufacturing capacity and careful management of turnaround times. Administering the therapy also requires specialized protocols to handle known CAR-T toxicities, particularly cytokine release syndrome and neurotoxicity.

Regulators in other countries may use the FDA's action as a reference point in their own review processes. Patient advocates have underscored the urgency of equitable access: CAR-T therapies are among the most expensive treatments in oncology, and delivery remains concentrated in major academic and specialty centers, creating geographic and financial barriers for patients who might otherwise qualify.